Similar articles

• Re: Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid.

  Diel IJ, Bergner R. Diel IJ, et al. Oncologist. 2005 Jan;10(1):82-3; author reply 84-7. doi: 10.1634/theoncologist.10-1-82. Oncologist. 2005. PMID: 15632256 No abstract available.
• "Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe.

  Lugassy G. Lugassy G. Oncologist. 2005 May;10(5):309-10; author reply 311-2. doi: 10.1634/theoncologist.10-5-309. Oncologist. 2005. PMID: 15851782 No abstract available.
• A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.

  Berenson JR, Vescio R, Henick K, Nishikubo C, Rettig M, Swift RA, Conde F, Von Teichert JM. Berenson JR, et al. Cancer. 2001 Jan 1;91(1):144-54. doi: 10.1002/1097-0142(20010101)91:1<144::aid-cncr19>3.0.co;2-q. Cancer. 2001. PMID: 11148571 Clinical Trial.
• Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.

  Wellington K, Goa KL. Wellington K, et al. Drugs. 2003;63(4):417-37. doi: 10.2165/00003495-200363040-00009. Drugs. 2003. PMID: 12558465 Review.
• Zoledronic acid: a new parenteral bisphosphonate.

  Li EC, Davis LE. Li EC, et al. Clin Ther. 2003 Nov;25(11):2669-708. doi: 10.1016/s0149-2918(03)80327-2. Clin Ther. 2003. PMID: 14693298 Review.